Making progress towards a better pathophysiological understanding and more promising therapeutic options for treating non-alcoholic steatohepatitis (NASH) / DASH (dysmetabolism associated steatohepatitis)

The prevalence of non-alcoholic fatty liver disease (NAFLD) and its advanced form, i.e. non-alcoholic steatohepatitis (NASH), in the general population are increasing worldwide, reaching 45 and 6.5%, respectively [1,2]. NAFLD, and especially NASH, have been associated with increased cardiovascular (CV) morbidity and mortality, as well as all-cause death and cancer development [3 –12]. Furthermore, there is a bidirectional relationship between NAFLD/NASH and type 2 diabetes mellitus (T2DM). Indeed, in T2DM patients, the prevalence of NAFLD may exceed 70%, whereas for NASH it can reach 50% [13].

Source: Metabolism - Clinical and Experimental - August 5, 2020 Category: Biomedical Science Authors: Niki Katsiki, Christos Mantzoros Tags: Editorial Source Type: research